Has anyone had micro fat grafting?

Options
1565759616268

Comments

  • kriserts
    kriserts Member Posts: 224
    edited March 2012

    re: terminology, I'm finding you should ask if they do fat grafting, or "total" fat grafting as reconstruction. The first implies FG around an implant. The second implies Brava.

    I'm having to call around the different docs my insurance company says do FG, in order to make a case for using Dr. Ahn. My insurance co probably thinks I want to do FG around an implant. I find when you ask the docs about FG, they say they do it, but when you mention total FG as reconstruction, with Brava, they don't.

  • gonnabperky
    gonnabperky Member Posts: 2
    edited March 2012

    Hi All,

    I'm new here so I appologize if this nfo is redundant. I found 3 people who do FG in the area commutable from NYC you may or may not know of:

    Christina Ahn - http://nycbreastreconstruction.com in NYC 212 717-8860 BRAVA Affiliated with NYU

    Johns Hopkins Hospital in Baltimore,MD - Dr.Gedge David Rosson.
    http://www.hopkinsmedicine.org/avon_foundation_breast_center/treatments_services/reconstructive_breast_surgery/    He also does (non-guarantee to work for everyone) nerve reconstruction. Non-BRAVA, but JH has been offering this for over 2 years and are great at answering questions on the phone. Laura Gifford is co-ordinator at 410 502-316. Apt info is Linda at 443 287-2778.

    Dr. Anya Kishinevsky - http://www.anyakishinevskymd.com/html/reconstruction.html  in CT 203 659-9999. non-BRAVA .  Gave great info on the phone as and was very sensitive and caring..

    Though I haven't given up on the idea of going to Fl for Dr. Kourhi, but I love and trust my onc surgeon in NY and prefer not to give him up.

    Best of luck to us all.

  • dancetrancer
    dancetrancer Member Posts: 4,039
    edited March 2012

    meny and truebff - you may want to check out this thread I just started about timing of treatments:

    optimal sequence for various treatments (rads, chemo, hormonal) 

  • truebff
    truebff Member Posts: 642
    edited March 2012

    Thanks, dt, that helped ease my mind about being held off til 15 weeks. So much confusion!!

  • dancetrancer
    dancetrancer Member Posts: 4,039
    edited March 2012

    I had to wait til 20 weeks, so I understand the anxiety! HTH! 

  • meny
    meny Member Posts: 29
    edited March 2012

    Thanks dt & trubff.  Maybe mine was referring to DCIS only?  no chemo or HT. I don't know anything about scheduling oncotypes either.  It's just seems  "standard to do lumpectomy followed by rads at 6-8 weeks" for DCIS.    In any case I'll send that to her and ask.  Trubff  I'll PM you the info if you want.   

  • meny
    meny Member Posts: 29
    edited March 2012

    I just read the report you linked to DT - and I won't pretend to understand most of it - but it seems it's full of contradictions.   In one study it says 6 weeks, in another 20 weeks.  Maybe I don't know how to read these reports yet but it sounds like no one really knows!  Which is what I"m beginning to suspect in general.   Here's some of it below - there's lots more.   

    RT DELAY WHEN GIVEN AS SOLE MODALITY AFTER BCS OR M

    As already discussed, it is well known that more than half of the patients receiving RT after BCS or M are delayed because of lack of equipment and personnel, even in developed countries [13]; the percentage can be even more substantial for countries with limited resources [9]. For the latter, question even arises as to whether there is enough availability of RT machinery for every early breast cancer patient in need. From all the previous data combined, we were able to reach the conclusion in our previous report that a delay of RT of more than 8-12 weeks after surgery adversely affects local control [5].

    Although data on survival are inconclusive and not definitive, given the well-established conclusion of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), (being that for any four local recurrences avoided, one breast cancer death is avoided), we cannot assume that any impact of a delay on RT administration on local recurrence does not affect survival [15]. Moreover, since this impact on survival is seen on data with long (15 years) follow-up and given the characteristics of the relevant studies (small studies, with short follow-up), it is evident why a detriment on survival could not be detected [15-17]. Indeed, the only direct evidence, until our previous report, existing on the impact of a delay in RT administration after BCS on survival, comes from the large evaluation of the Surveillance, Epidemiology, and End Results (SEER)-Medicare data involving almost 14,000 women [18]. In the 3% of them who received RT >3 months after surgery, survival was severely impaired (hazard ratio, 3.84).

    More recent studies have been published in the last 3 years: The Florence experience study, involving almost 5,000 women and evaluating the relationship between RT delay and local recurrence, was unable to detect a surgery-RT interval that resulted in increased local recurrence [19]. Authors of the study argue that local recurrence does not depend on the delay of RT administration as much as it does depend on tumors' and patients' characteristics. They only found a statistically significant relevance between local recurrence and RT delay in patients receiving chemoT (hazard ratio, 1.59) and conclude that "waiting lists" should become "programming lists" with patients being scheduled depending on their individual and tumor characteristics and their prognostic significance.

    The study by Olivotto et al. [20] has evaluated the BCS-RT interval that adversely affects local control and survival. With a total of almost 6,500 women, they were able to detect a statistically significant interval of >20 weeks after surgery that resulted in impaired local recurrence-free, distant recurrence-free, and breast cancer-specific survival. Therefore, authors of the study suggest the 20-week interval should not be overlooked, while patients should be given the time for their breast to heal and their informed decisions to be made within that interval.

    Finally, the most recently published study by Punglia et al., involving >18,000 women treated with BCS and receiving no chemoT, has shown that delays of >6 weeks can be detrimental for patients in terms of a local recurrence, while there exists a continuous relationship between BCS-RT intervals and local recurrence in older women with early stage breast cancer [10].

    Therefore, more recent and reliable evidence, coming within the last 3 years, pertains to the maximum acceptable surgery (mainly BCS)-RT intervals that do not jeopardize patients' local and distant control and survival. This is robust, well-conducted, and comes from large centers' data. However, results from these studies are not uniform: the 6-week to 20-week interval is far from coinciding, whereas the Florence experience does not even detect a concrete detrimental delay. However, in our mind, two messages arise from all of these data.

    First, with the nonuniformity of breast cancer disease being more widely recognized, it becomes evident that studies will never coincide as long as they involve patients with various prognostic and predictive factors of the disease because, obviously, the impact of RT delay on their risk of local recurrence is not the same for every early breast cancer patient. Therefore, before we rush to convince a patient that their delay in receiving their adjuvant RT poses no risks for their health, we might as well consider the individual's and tumor's unique probability for relapse. In that direction, the sense of prognostic factors attains additional importance for departmental and health policy design, implementation, and scheduling.

    Second, it is obvious from existing studies that, although a long delay of >6, 8, 12, or 20 weeks should be avoided, a minimum interval of up to 6 weeks is not harmful and, moreover, might be essential for the breast to heal and the patient to be psychologically and physically prepared for another step in her breast cancer odyssey. Therefore, with proper resource planning, timing can be an advantage instead of being a drawback; moreover, present data suggest that a multidisciplinary upfront approach is essential and that RT appointments should not be given by secretaries but instead by radiation oncologists.

  • dancetrancer
    dancetrancer Member Posts: 4,039
    edited March 2012
    Oh, I hate to derail this thread as it is for fat grafting - i will just say that yes, there is never a definitive answer it seems, but if you read the conclusion I posted you'll see that the authors of the study tried to sum up all of the conflicting studies and evidence with their overall opinion.  If you want to discuss it more, can you comment in the other other thread?  Just don't want to derail this one from it's intent! Smile
  • beacher4209
    beacher4209 Member Posts: 540
    edited March 2012

    hello , i wanted to ask if anyone has or know of anyone that has had a skin graft transfer( thats what im calling it not sure if thats is the medical term) ? as you know i had my fg done about 3 weeks ago feb.22nd i had my 500 cc implant removed and replaced with 250cc and fg 200cc. also on my nonmx side took out the 250cc and relocated the nipple. so my non mx side is a beauty,but i stll have the hamburger bun on mx side. It is also tight still. my ps wants to add a football shape piece of skin taken from me to add more skin ,to get the flat look out,i believe he will fg then some more. it makes sense but where he wants to take the skin from is under my armpit where i have had alot of scar tissue issues....So if anyone can let me know more about this that would be helpful thanks take care all:)

  • Anonymous
    Anonymous Member Posts: 1,376
    edited March 2012

    beacher- I haven't heard of that procedure before and not sure I understand.  You basically just had another exchange, though, and it seems like it'll take the implant awhile to "drop and fluff" just like before.  I remember right after exchange my foobs did look like squashed hamburger buns but gradually settled and looked much better a few months later.  Is Dr. A proposing this right away?  Also, have you had nodes removed from both sides because, if so, I would caution you about is having skin removed from under the arms.  It seems like this would put you at a higher risk of LE.  Why doesn't he think that fat grafting alone will improve things?  

  • beacher4209
    beacher4209 Member Posts: 540
    edited March 2012

    Hi Kate,  my foob never dropped and fluffed last exchange so im assuming i just am lacking skin.no way am i letting him remove anything from under my arm i too am dealing with scar tissue issues under there. He s does not want to do this for a while its kinda waiting to see what the fg does next.but no matteer what there is just not enough skin. im not sure what i will do at this point....

  • meny
    meny Member Posts: 29
    edited March 2012
    Sorry DT, you're right - didn't mean to derail - wasn't thinking!Smile
  • Anonymous
    Anonymous Member Posts: 1,376
    edited March 2012

    beacher- Sorry!  I was really hoping this surgery was going to fix everything for you.  I know how disappointing it is.  I hope things are at least somewhat better.  I wonder if the BRAVA would help with your skin issues?  I don't know much about it.  Has Dr. A ever used it in his practice do you know?  Does having the smaller implants help with some of the pain at least?  I know it did for me.  (((hugs)))

  • beacher4209
    beacher4209 Member Posts: 540
    edited March 2012

    ya Kate i think the smaller implant and fg helped with the foob except that its a hamburg bun. But my under arm is still so painfull, they took the scar tissue out and clips but its still pulling i think the whole node thing is the culprit?? i dont know  but its wait and see for a while Thanks Kate 

  • rk85
    rk85 Member Posts: 145
    edited March 2012

    Kate, your suggestion about Brava sounds right on!  I've seen documentaries where they had to stretch skin to cover future surgeries, and they put an inflatable implant under the skin and stretch it slowly over weeks.  The skin stretches and grows to cover the implant and the surgeon has the skin he needs to do the operation!  (I saw this done for conjoined twins who were going to be separated at the skull and they needed enough skin to cover both heads once separated)

     Brava does the same thing with the constant vacuum and stretching.

    Also, what about the skin they are able to grow in sheets in the lab to cover grafts for burn patients?!?  I read about this stuff but why don't they have it in use yet!

    Beacher, your trouble sounds like it may be something PT could help.  Now that the clips are out, maybe you just need to have some scar tissue released, or any of the other many issues PT can help with. 

  • LilliM
    LilliM Member Posts: 29
    edited March 2012
    Hi Beacher:
    Do you know if your PS uses the Brava? I had lumpectomy and rads and used the Brava to stretch my skin and underlying tissue before my first fat grafting in Jan. I'm currently using the Brava for three months until my next fat grafting in April. It's my understanding that the Brava generally isn't used for implant exchange presumably because replacing a larger implant with a smaller one leaves enough space for the fat grafting. But it sounds like your radiated skin is still too tight for even the smaller 250cc implant and 200cc fat graft. Provided the Brava is safe to use with implants, it might make sense in your case. IMO, the Brava would be a lot less invasive than a skin graft. I share your concern about surgery under the arm. This may be an idea worth running by your PS.
  • geewhiz
    geewhiz Member Posts: 1,439
    edited March 2012

    Dr Khouri initially had me buy the BRAVA to use with my implants. I used it for about a week then he had me stop. He no longer uses it in ladies with implants to my knowledge. I haven't spoken with him in a few months, so perhaps that has changed again.

    I do think Kate is right. This is all new, so he tries things out. Some things work, some things don't. The axillary incisions were a HUGE mistake for me.

  • Anonymous
    Anonymous Member Posts: 1,376
    edited March 2012

    beacher- Just doing the fat grafting may improve the skin enough over time to allow for another FG.  I'm wondering if Dr. A removed the implants all together with the 2nd round if you could then do the BRAVA for a 3rd round to get to the size you want to be?  I think I saw an ad somewhere- FOR SALE- BRAVA SYSTEM, BARELY USED STILL IN PACKAGING.  MAKE ME AN OFFER.  Contact- geewhiz

    geewhiz- Well, that was an expensive experiment.  A week?  Seriously?  I think surgeons should say either a) I've done this hundreds of times with great success, or b) I've only tried this ________ times with good success or c) I've never tried this before.  Are you willing to give it a shot?  At least we know what we're signing up for.  

  • LilliM
    LilliM Member Posts: 29
    edited March 2012

    Kate33:

    Not necessarily an experiment.  Dr. K sometimes has patients wear the Brava for very short periods of time, as little as a few days, with clear objectives in mind, such as releasing scar tissue, etc. 

  • leeinfl
    leeinfl Member Posts: 317
    edited March 2012

    I wore my Brava dome for 3 or 4 days, can't remember but it was 24/7.  Lilli, you are absolutely correct, Dr. K does indeed "customize" the protocol for each of his patients.  Thank God, he doesn't treat us like a "one size fits all" and thinks outside the box in order to achieve the best results.  I don't consider my few days of Brava an expensive experiment at all - it did exactly what Dr. K intended it to do: loosen the skin adhesion to create the space necessary for successful fat grafting.

  • geewhiz
    geewhiz Member Posts: 1,439
    edited March 2012

    No LilliM, I was an experiment I feel. Its a lot of uncharted territory. I trust Dr K though. The initial hope was to use BRAVA to create the scaffolds even with implants in place. I was to wear them for months. And Kate33, I bought 2 sets, medium and large. I have the second set still untouched in the box. That turned out to not work out for me and other women for various reasons. Implant rupture possibilities was one of them.

    I do think if I called up and wanted to return the unused ones, they would accomodate me somehow. My sister lives down there and every time I throw the kids in the van to hit the beach, I try to remember to throw those in the back...but they haven't made it down there yet!



  • rk85
    rk85 Member Posts: 145
    edited March 2012

    Geewhiz, I would call about returning the domes - I was told that I could exchange new ones with the plastic still on for a different size, but they were not returnable.  However I guess it doesn't hurt to try!  If all else fails, you can always sell them.  I recall new ones sell for $300 from Brava and a little less from authorized sellers on ebay.

  • beacher4209
    beacher4209 Member Posts: 540
    edited March 2012

    who invented the brava? and is it onlt used on bc patients?or is it used for other diffrent surgeries where people need stretching and what else does it do besides strtch?cause tissue expanders do that ? thanks

  • LilliM
    LilliM Member Posts: 29
    edited March 2012

    Hi Beacher: 

    Dr. Khouri invented the Brava. Lots of people use the Brava, not just bc patients. In fact, it was first developed for bust enhancement. Show girls in Las Vegas wear it before performances; celebrities wear it before walking the red carpet. Some women wanting bigger breasts, but not wanting to undergo fat grafting surgery, simply wear it to bed every night. And then there are the men who wear it...but that's another story. There's lots of information at this site: http://www.mybrava.com/home.asp

  • ZTeam
    ZTeam Member Posts: 44
    edited March 2012

    Hi All,

    I've been looking into reconstruction with fat grafting and the Brava following a BMX. Does anyone know how long you have to wait post radiation to begin wearing the Brava? 

    Thanks! 

  • rk85
    rk85 Member Posts: 145
    edited March 2012

    Beacher, Dr. Khouri invented the Brava.  It is used for breast cancer patients as well as breast augmentation in women without BC, and it can be used alone (for augmentation) or before fat grafting augmentation surgery.  I am not aware that it is used on any other parts of the body than the breasts.

    The difference between tissue expanders and brava is that Brava is an external device, which expands by creating a vacuum around the breasts.  Tissue expanders are surgically placed under the skin and expanded via fills.

  • whippetmom
    whippetmom Member Posts: 6,920
    edited March 2012

    Kate:  I need a Northern California PS - San Jose, Palo Alto, San Francisco - who is using Dr. Khouri's method.  Do you have one? Not for me - for a referral...

    Thanks!

  • Anonymous
    Anonymous Member Posts: 1,376
    edited March 2012

    whippetmom - Dr. Lauren Greenberg in Palo Alto, CA uses the Khouri method: http://www.laurengreenbergmd.com

    geewhiz, I may be interested in purchasing your large domes :-)

  • Anonymous
    Anonymous Member Posts: 1,376
    edited March 2012

    whippetmom- I'm not home right now but Dr Greenberg was the name that came to mind, too. I'll check my list when I get home and see if I have any other names for you.

  • hrf
    hrf Member Posts: 3,225
    edited March 2012
    Cytori Breast Reconstruction Cell Therapy Trial Results Published ZUG, SWITZERLAND and SAN DIEGO, CA, Mar 19, 2012 (MARKETWIRE via COMTEX) -- Cytori Therapeutics CYTX -6.39% announced today the publication of RESTORE-2 trial results in the peer-reviewed European Journal of Surgical Oncology.RESTORE-2 is a 71 patient multi-center, prospective clinical trial using autologous adipose-derived regenerative cell (ADRC)-enriched fat grafting for reconstruction of the breast after cancer surgery. The majority of patients underwent radiation prior to the procedure, creating an unfavorable ischemic environment for which breast reconstruction with ADRC-enriched fat grafting appears to be ideally suited.Key findings of the trial were: -- High rates of investigator (85%) and patient (75%) satisfaction with the overall treatment results at 12 months; -- High rates of investigator (87%) and patient (67%) satisfaction with overall breast deformity (based on functional and cosmetic outcomes) at 12 months; -- Improved breast contour at both six and 12 months, demonstrated by blinded MRI assessment; and -- No local cancer recurrences or serious adverse events related to the ADRC-enriched fat grafting procedure. "Following cancer treatment, the patient's breast tissue can suffer from radiation injury, scarring and tight skin," said Consultant Plastic and Reconstructive Surgeon Mrs. Eva Weiler-Mithoff, co-principal investigator for RESTORE-2 at the NHS Glasgow Royal Infirmary Hospital. "This new technique is exciting because it may offer the opportunity to resolve some of the most difficult to treat conditions where other approaches, including fat alone, do not achieve satisfactory results."ADRC-enriched partial mastectomy breast reconstruction is marketed in the EU as the RESTORE Procedure and represents an innovative treatment option with significant cost savings potential. The procedure can be performed on an outpatient basis. Satisfactory results can be achieved in a single procedure for the majority of patients. In contrast, competitive approaches are more costly with lengthy hospital stays, require repeat procedures and increase the overall burden on the healthcare system. Furthermore, because of these limitations, physicians are often reluctant to recommend reconstruction for patients with partial mastectomy defects and radiation-induced damage in the breast.Each year, approximately 450,000 European women are diagnosed with breast cancer. Of the newly diagnosed breast cancer cases, 70-80% are eligible for breast conserving surgery, where only a portion of the breast is removed rather than the full breast. In the European G5, there are an estimated 1.25 million women who have undergone partial mastectomy. The majority of these patients are left with a sizeable volume defect, scarring and often radiation damage."Given that there is no widely accepted reconstructive option available today for partial mastectomy patients, this procedure could well address this substantial unmet need and help complete the overall cancer treatment," said Marc H. Hedrick, president of Cytori.The European Journal of Surgical Oncology is the official journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.About the RESTORE ProcedureDuring the RESTORE Procedure, fat is taken from the patient's stomach, hips, thighs, or other areas by liposuction. Some of the tissue is processed in Cytori's Celution(R) system to extract the patient's own regenerative cells which occur naturally inside the tissue. The extracted cells are then combined with the remaining fat tissue, forming an ADRC-enriched fat graft that is injected into the breast to restore its natural look and feel. In addition to providing an entirely natural reconstruction, the procedure is minimally invasive with the potential to reduce scarring. The Celution(R) system is not commercially available in the United States.About the RESTORE-2 TrialRESTORE-2 is a 71 patient European post-marketing trial primarily intended to measure patient and physician satisfaction in reconstructing the breast utilizing the Celution(R) system. The trial took place at the following sites: Hospital General Universitario Gregorio Maranon in Madrid, Spain, Glasgow Royal Infirmary in Glasgow, Scotland, KU Leuven University Hospitals in Leuven, Belgium, Azienda Ospedaliero Universitaria Careggi in Florence, Italy, Instituto Valenciano Oncologia in Valencia, Spain, Norfolk and Norwich University Hospital in Norwich, England, and Jules Bordet Institute of Cancer in Brussels, Belgium.About CytoriCytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow. As a result, we believe these cells can be applied across multiple ischemic conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution(R) system product family. www.cytori.comCautionary Statement Regarding Forward-Looking StatementsThis press release includes forward-looking statements regarding events, trends and business prospects, which could affect our future operating results and financial position, such as our expectation of increased hospital and patient availability, and our expectation of acceptance of the treatment for lumpectomy and radiation scarring. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include regulatory uncertainties, the perceived quality of our clinical data, physician and patient acceptance of our technology, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2011. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release. CONTACT US Megan McCormick mmccormick@cytori.com +1.858.875.5279 EU Stefanie Bacher sbacher@cytori.com +44 77 0202 7053 (mobile) SOURCE: Cytori Therapeutics, Inc.

Categories